- £198.21bn
- £217.54bn
- $54.07bn
- 85
- 16
- 86
- 71
REG - AstraZeneca PLC - Imfinzi sustained overall survival in CASPIAN
AnnouncementREG - AstraZeneca PLC - Enhertu DESTINY-Gastric01 results from ASCO 2020
AnnouncementREG - AstraZeneca PLC - Tagrisso unprecedented adjuvant lung cancer data
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Enhertu US orphan designation in gastric cancer
AnnouncementREG - AstraZeneca PLC - AstraZeneca advances response to COVID-19 outbreak
AnnouncementREG - AstraZeneca PLC - Lynparza approved in the US for prostate cancer
AnnouncementREG - AstraZeneca PLC - Bevespi Aerosphere approved in China for COPD
AnnouncementREG - AstraZeneca PLC - Enhertu US Breakthrough status for lung cancer
AnnouncementREG - AstraZeneca PLC - Brazikumab rights recovered by AstraZeneca
AnnouncementREG - AstraZeneca PLC - Lynparza gets broader US ovarian cancer approval
AnnouncementREG - AstraZeneca PLC - Enhertu designated gastric cancer BTD
AnnouncementREG - AstraZeneca PLC - Farxiga approved by FDA for heart failure (HFrEF)
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Result of AGM
AnnouncementREG - AstraZeneca PLC - AZN: first-quarter 2020 results
AnnouncementREG - AstraZeneca PLC - Lynparza shows overall survival in prostate cancer
AnnouncementREG - AstraZeneca PLC - Changes to arrangements for AGM
AnnouncementREG - AstraZeneca PLC - Tagrisso adjuvant trial overwhelmingly positive
Announcement